Summary: Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's 'string of pearls' strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results.
